Loading...
XASE
PLX
Market cap143mUSD
Jul 09, Last price  
2.37
1D
-0.42%
1Q
3.04%
Jan 2017
-46.74%
IPO
-97.10%
Name

Protalix Biotherapeutics Inc

Chart & Performance

D1W1MN
XASE:PLX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
21.93%
Rev. gr., 5y
-3.46%
Revenues
53m
-1.23%
150,00000388,00011,244,0008,386,00034,424,00011,513,00015,160,0004,364,0009,199,00021,078,00034,240,00054,693,00062,898,00038,350,00047,638,00065,494,00053,399,00052,744,000
Net income
-7m
L
-9,427,000-22,481,000-22,414,000-31,440,000-28,998,000-36,529,000-11,618,000-27,790,000-29,943,00058,037,000-29,365,000-83,440,000-26,457,000-18,276,000-6,523,000-27,582,000-14,927,0008,312,0002,932,000-6,604,000
CFO
-12m
L
-5,091,000-10,449,000-16,015,00044,452,000-38,464,000-23,570,000635,000-30,653,000-29,281,000-24,284,000-32,098,000-9,994,000-7,742,000-19,358,000-26,106,000-10,285,000-25,000,000-1,318,0008,674,000-11,993,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
URL
https://protalix.com/
IPO date
Sep 06, 2010
Employees
193
Domiciled in
IL
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT